Baxter in Singapore

110Products sold in more than countries

70Employees located in approx. countries

27Manufacturing facilities in countries

Baxter is a global diversified healthcare company

BioScience productsRecombinant and plasma-based therapies that are used to treat:l Haemophilia and other

bleeding disordersl Immune disorders

Other products:l BioSurgery products for

haemostasis, wound healing and tissue sealing

l Vaccines for pandemic influen-za, tick-borne encephalitis, and meningococcal C meningitis

Medical productsl IV solutions and

parenteral nutrition productsl Premixed drugs in

flexible containersl Electronic infusion pumps and

administration setsl Dialysis systems and solutionsl Inhaled anesthetic agents

6,000,000 times a day Baxter products are infused, injected or inhaled to treat life-threatening acute or chronic

medical conditions

Delivering healthcare to Asia

l Asia Pacific accounts for 16% of total Baxter sales worldwide

l It is a regional leader in peritoneal dialysis, anaesthesia, haemophilia, infusion medication delivery systems and parenteral nutrition

l 12 regional manufacturing facilities are located in Australia, China, India, Japan, the Philippines and Singapore

Since 1978, Baxter has invested significantly in its Singapore manufacturing facilities. Today it exports high-value products to markets around the world, leveraging the city-state as a base for regional growth

Woodlands

Regional HQ

When fully functioning in 2014, Baxter’s bioscience manufacturing facility in Woodlands will produce ADVAtE, which treats haemophilia A. Singapore is home to eight biotech manufacturing facilities that collectively have invested approximately S$2.4 billion in the country

Baxter’s Woodlands facility is one of the company’s largest and most global manufacturing locations, shipping products to more than 61 countries

Baxter’s home in the heart of Asia

Investment timeline: Over the years, Baxter has increasingly produced higher-tech, higher-value products

2013Establishes regional

HQ for Emerging Asia

2014Singapore facilty

begins commercial production of

ADVAtE

2009Singapore becomes

Baxter’s largest producer of IV sets and among its top

three for infusion pumps globally

1983Moves to bigger plant in Woodlands, making infusion pumps and

dialysis solutions bags

Sets up first plant in Marsiling,

making IV sets

1978

reasons why Baxter chose Singapore for its bioscience facility

5Ready pool of international talent

Singapore has a productive and skilled labour-force that makes it a conducive

place for businesses to attract and retain talent. through local partnerships, Baxter was able to create a workforce

at its new facility consisting of 90% high-tech workers

Strong ecosystem and IP protectionSingapore has a thriving ecosystem to support biotech manufacturing, with

resources including the vibrant research hub Biopolis. this is

complemented by strong IP protection – in 2012, the World Economic Forum

ranked Singapore as Asia’s No 1

A commitment to grow biotech manufacturing

Biotech manufacturing is a key focus of Singapore’s biomedical sciences industry. Regulatory compliance and

quality is also an area in which Singapore has demonstrated a strong

track record

Specialised infrastructurethird party logistics players such as

Zuellig Pharma, tee Hai, tNt and DHL all have life science logistics hubs in Singapore providing cold chain

services. Coolport@Changi, Asia’s first on-airport perishables handling centre, ensures cold supply chain integrity for

biopharmaceutical products

Political and social stabilitySingapore’s safe and stable political climate gave Baxter the

confidence to make the investment needed to build their biotech facility. the World Bank consistently ranks Singapore among

the top investment destinations in Asia